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ABSTRACT
Of 197 patients referred for colposcopy who underwent repeat Pap smears and colposcopic
biopsies (when indicated), histologie evidence of human papillomavirus (HPV) infection
involving the endocervix, cervix, or vagina or all three sites was documented in 109 biopsies.
Sixty-six (61 %) had normal Pap smears at the time of colposcopy. Despite a specificity of 92%
for detecting HPV, the Pap smear demonstrated a low sensitivity (39%), with a positive and
negative predictive test value of 88% and 50%, respectively. In patients with biopsies
revealing HPV infection without associated dysplasia, false negative Pap smears were found
most often in women with strictly vaginal HPV (74%) (P < 0.05), followed by those with
coexistent cervical and vaginal HPV (65%), and then by those with solely cervical HPV (51 %).
We question the use of the Pap smear for the detection of lower genital tract HPV, particularly
in patients with only vaginal involvement, especially when the smear is repeated at the time
of colposcopy. Benefits and disadvantages of other screening tests for HPV are discussed.
(J GYNECOL SURG 7:183, 1991)
INTRODUCTION
Screening for cervical cancer is based on identifying and eradicating dysplasia prior to its progressionto fra k carcinoma. Cytologie screening remains the mainstay in the detection of women with
pre-malignant (cervical intra-epithelial neoplasia) (CIN) and malignant changes of the cervix. Timely
diagnosis of pre-malignant and malignant changes of the cervix has significantly reduced the morbidity and
mortality associated with squamous cell carcinoma of the cervix.
HPV is believed to be significantly associated with the neoplastic transformation of squamous cells in the
lower genital tract.4-5 HPV infection may involve viral replication and insinuation of viral genome within the
infected host's nuclear genetic material.6 The site of infection and subsequent neoplastic transformation is
often multifocal. Evidence of HPV has been found in malignancies involving the cervix, vagina, and vulva,
as well as premalignant lesions of these areas.710
Accuracy in diagnosing HPV infection depends on various skills. The clinical examiner must be able to
visualize anatomic features suggestive of warty change. A carefully performed cytologie screen should reveal
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characteristic features, such as koilocytosis and dyskeratosis." Results of molecular virology and DNA
hybridization analysis may further identify potentially oncogenic subtypes.I2-13 Finally, histologie diagnosis
of biopsy specimens of lesions should be confirmatory. '4 Although some investigators suggest that the Pap
smear is adequate for the primary screening of HPV, others doubt its sensitivity and accuracy. Likewise,
controversy surrounds the sensitivity of the Pap smear as the sole screening technique in detecting CIN,
cervical carcinoma, and other premalignant lesions of the lower genital tract.15-'6
Koilocytotic changes associated with HPV may decrease the sensitivity of the screening Pap smear for
detecting CIN. '7 However, CIN and HPV often coexist. Studies have proven that cytologie evidence of HPV
followed by colposcopic evaluation and directed biopsies improves the accuracy of detecting CIN when
conditions occur concomitantly.18-19 Thus, it may be advisable to perform colposcopy on all patients with
cytologie evidence of HPV.20
The purpose of this investigation is threefold. First, we wish to evaluate the adequacy of the Pap smear as
a screening method for the detection of HPV infection of the lower genital tract. Second, we wish to assess
whether the Pap smear was a more sensitive screen for the population of patients with HPV and histologie
evidence of CIN as opposed to HPV alone. Finally, we hope to determine what effect the site of HPV
infection, be it vaginal, cervical, or both, has on the sensitivity and accuracy of the Pap smear.
SUBJECTS AND METHODS
Between July 1986 and April 1989, 197 consecutive women were referred to the Kaiser Permanente-
Anaheim colposcopy clinic for evaluation of suspected lower genital tract pathology after noncolposcopic
directed biopsy, suspicious lesion(s) seen on routine examination, or abnormal cervical cytology. Abnormal
cytology was defined as any Pap smear that did not meet criteria for Class I. The distribution of referral
diagnoses of the patients included in this study can be found in Table 1. At colposcopy, all patients first
underwent repeat Pap smear tests. A wooden spatula was then used to scrape the cervical transformation zone,
followed by endocervical sampling with an endocervical brush. Patients who had undergone prior total
hysterectomy (n = 7) had upper vaginal cytologie samples obtained using only the spatula. The time interval
between the initial abnormal Pap smear and subsequent colposcopic evaluation and repeat Pap testing was
21-90 days.
Following repeat Pap smear, colposcopy was performed after the application of dilute acetic acid to the
cervix and vagina. Directed biopsies were taken when suspicious areas were visualized, and endocervical
curettage was performed if colposcopic imaging was inadequate or when no exocervical lesions were visible.
Cytopathologists and histopathologists interpreting specimens were blinded as to the patients' identity so
not to bias results. All histologie specimens were reviewed by a second pathologist at the termination of the
study to confirm pathologic diagnoses.
RESULTS
Of the original 197 patients entered, 109 women (56%) demonstrated histologie evidence of HPV on
biopsies of the endocervix, cervix, or vagina. All exhibited characteristic changes of HPV, such as
Table 1. Reasons For Referral to Colposcopy Clinic in
Study Population
Method Diagnosis n (197)
Pap smear CIN 64
HPV 45
CIN and HPV 5
Inconclusive for pathology 69
Examination Visible lesion on lower 8
genital tract
Positive noncolposcopic lower 6
genital tract biopsy for CIN or HPV
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FIG. 1. Cervical biopsy in a patient with a negative Pap smear, showing features of HPV with CIN I at x20 (A) and
x40(B).
koilocytosis, nuclear atypia, dyskeratosis, and acanthosis. Vaginal biopsies deemed abnormal similarly
contained histologie correlates of HPV, as previously described.21 Sixty-six of 109 patients with HPV proven
on biopsy (61%) had normal cytology on their repeated (study) Pap smears (Fig. 1). Table 2 lists study Pap
smear results for patients with concomitant (histologie) HPV and CIN and compares these findings to women
with HPV without CIN. The study Pap smear was unable to detect the existing abnormality in 54/87 patients
(62%) with only HPV on biopsy. This was not significantly different from the 55% (12/22) false negative Pap
smear finding in patients with coexisting disease. However, of 22 patients with CIN without histologie
features of HPV, only 6 (27%) had negative Pap smears.
The study Pap smear showed a low sensitivity (39%) yet high specificity (92%) for detecting HPV infection
of the lower genital tract. The positive and negative predictive value of the Pap smear in this population was
88% and 50%, respectively (Table 3).
Table 2. Pap Smear Sensitivity and Detection of HPV of Lower
Genital Tract: Influence of Concomitant Dysplasia
Positive HPV on biopsy
With CIN Without CIN All patients
Pap smear positive 10
Pap smear negative 12
Total 22








NS (p = 0.52) by Chi square.
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Table 3. Sensitivity, Specificity, Positive and Negative
Predictive Value of the Pap Smear in Detection of HPV of
Female Lower Genital Tract
Colposcopy-directed biopsy















Positive predictive value = 88%.
Negative predictive value = 50%.
Reviewing results of patients whose biopsies showed histologie evidence of HPV without associated CIN,
the Pap smear was significantly least helpful in identifying those with only vaginal HPV involvement, with
74% false negatives. Patients with cervical and vaginal HPV demonstrated a 65% false negative rate, whereas
women with only cervical HPV had 51% false readings (Fig. 2).
DISCUSSION
Identification of the patient with evidence of HPV allows the clinician to counsel the patient and her partner
as to the potential for viral transmission. Also, the increased risk of developing neoplasia, followed by a
discussion of the various treatment modalities available to the patient, may be addressed. Although a range of
therapeutic modalities, such as laser vaporization,2224 cryosurgery,25-26 intralesional injection of interfer-
on 27.28 ancj tng appi¡cation of 5-fluorouracil,29-30 are available, success with regard to complete eradication




cervix only cervix and vagina vagina only
Biopsy Site HPV Positive
Pap Negative Pap Positive
n=87 p < .05 when * compared to '
(Chi Square)
FIG. 2. Accuracy of the Pap smear. Detection of HPV of the lower genital tract with respect to lesion site.
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Our study questions the sensitivity of the Pap smear when dysplasia and HPV coexist. Unless patients were
diagnosed at primary screening, they are unlikely to ever undergo colposcopy, where the presence of HPV or
dysplasia can be visualized and affected areas biopsied. We, therefore, did not include the referral (first) Pap
smear in our analysis of the data, since it would reflect the bias of our selected colposcopy clinic population.
This study further suggests that the Pap smear is more sensitive as a screen for cervical HPV as opposed to
vaginal HPV. Most likely, this results from the traditional sampling of the endocervix and cervical portio,
where any vaginal cells obtained are from those sloughed onto the cervix or posterior fornix.
In patients with dysplasia, the value of repeat cytologie study during colposcopy has been considered
misleading.37 Up to a third of patients with normal cervical cytology on repeat examinations may have
dysplasia when biopsied. Our study agrees with these findings. We limited our population to patients at high
risk for abnormality. Thus, the likelihood of discovering pathology was increased.
The false negative rate of the Pap smear in our study actually may be underestimated because we
consistently performed Pap smear examinations using a wooden spatula and endocervical brush, whereas
these tools were not used consistently in the clinics that referred patients to the colposcopy clinic. Use of an
endocervical brush has been shown to improve the quality and sensitivity of the cytologie sample obtained.38
Previous reported reasons for failure of a Pap smear to detect existing abnormalities include improper
specimen collection, douching before the examination, poor instrumentation, delayed fixation, improper
specimen fixation, and poor laboratory performance.39 Since repeat examinations were performed in identical
fashion and processed by the same clinicians and staff, it is unlikely that these confounding variables had
much effect on our results.
Until improvements in the primary gynecologic screening examination for HPV occurs, we cannot expect
to reduce the true incidence of HPV in the community at large. Cytology combined with colposcopic
screening remains the most comprehensive and accurate method for detecting and localizing lower genital
tract HPV infection with or without associated dysplasia.40-41 Colposcopic screening of patients referred for
abnormal cervical cytology is of proven benefit in identifying lesions associated with HPV infection of the
cervix and vagina and is a superior screen compared to cytology alone.41-42 If performed concomitantly with
primary cervical cytology, sensitivity of the primary cancer screening examination is improved.43 The patient
with a vaginal or cervical lesion can be counseled immediately. Those with false negative colposcopic
findings benefit from further information afforded by the Pap smear. It has been suggested that follow-up
examinations after therapy for CIN or condyloma are most accurately performed when patients are screened
using cytology and colposcopy.44
Critics of colposcopy argue that the technique is expensive and time consuming, requires specialized
training to perform, and is not universally available to all gynecologists.45 Although simultaneous colposcopy
and cervical cytology has been described for over 30 years as a screening method for detecting cervical
dysplasia, it has not gained favor as a primary gynecologic screening procedure.46 Furthermore, it is unlikely
that this approach will gain popularity as a screening method in discovering viral infection, even though the
presence of HPV is linked to the subsequent development of neoplasia.
Because of the difficulties inherent in the use of colposcopy, other methods, such as cervicography, DNA
hybridization probe analysis of cervical cytologie samples, and use of the polymerase chain reaction
technology,47 M) have been suggested as primary screens. They may be technically difficult and not always
readily available. Furthermore, although cervicography has been shown to improve the sensitivity of the
primary cervical cancer screening examination,45 it offers little information about the rest of the genital tract.
Similar to a Pap test, results are not immediately available. This delay fosters noncompliance. In situ DNA
hybridization studies for detecting HPV are sensitive but nonspecific with respect to the site of infection.49
However, DNA typing may be of benefit when isolating HPV subtypes associated with oncogenic
transformation.51
Our study suggests that gynecologic examinations miss a significant number of patients with HPV infection
despite screening with cervical cytology. This is especially true of women with vaginal HPV involvement.
Perhaps improvement can be achieved if a more comprehensive approach to screening is used. This might
include consideration of the results of careful visual inspection of the entire lower genital tract (visual evidence
of a suspicious papillomatous lesion of the lower genital tract), the inclusion of vaginal sampling into the
cytologie screening technique, and scrutiny of patients with persistent clinical symptoms of HPV infection
(such as recurrent, unexplained vaginal infections or the presence of chronic pruritus). This may lead to the
performance of more confirmatory tests and will improve our ability to identify more accurately and counsel
these patients with a sexually transmissible viral infection.
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